In Phase C, contributors will get ABBV-744 and oral navitoclax. In Section D, members will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment right until disorder progression or maybe the contributors are unable to tolerate the study drugs. Attainable new strategies for your diagnosis and treatment of AML. (A) The https://sergioevjsd.blogvivi.com/32527098/the-fact-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-that-no-one-is-suggesting